Health Care & Life Sciences » Pharmaceuticals | Faron Pharmaceuticals Oyj

Faron Pharmaceuticals Oyj | Income Statement

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
169.90
729.90
377.40
780.50
-
16.80
Cost of Goods Sold (COGS) incl. D&A
132.50
370.60
151.00
-
66.60
-
Gross Income
37.40
359.30
226.50
-
66.60
-
SG&A Expense
1,846.50
1,438.00
4,970.50
9,511.70
19,336.90
17,795.30
EBIT
1,809.10
1,078.70
4,744.00
-
19,403.50
17,867
Unusual Expense
9.30
-
-
-
-
-
Non Operating Income/Expense
755.90
89.40
328.80
567.30
1,024.70
206.20
Interest Expense
239.50
117.60
45.70
22.10
66.60
108.80
Pretax Income
1,280.80
1,094.00
4,460.90
8,250.00
18,445.30
17,769.60
Income Tax
-
4.80
30.50
61.50
0.90
1.80
Consolidated Net Income
1,280.80
1,098.80
4,491.40
8,311.40
18,446.20
17,771.40
Net Income
1,280.80
1,098.80
4,491.40
8,311.40
18,446.20
17,771.40
Net Income After Extraordinaries
1,280.80
1,098.80
4,491.40
8,311.40
18,446.20
17,771.40
Net Income Available to Common
1,280.80
1,098.80
4,491.40
8,311.40
18,446.20
17,771.40
EPS (Basic)
0.88
0.73
0.22
0.51
0.67
0.58
Basic Shares Outstanding
23,111.70
23,111.70
20,686.90
23,979.70
27,887.90
30,749.60
EPS (Diluted)
0.06
0.05
0.22
0.35
0.66
0.58
Diluted Shares Outstanding
23,111.70
23,111.70
20,686.90
23,979.70
27,887.90
30,749.60
EBITDA
1,761.60
1,030.30
4,610.50
8,731.20
19,336.90
17,778.50
Non-Operating Interest Income
2.50
12.90
-
-
-
-

About Faron Pharmaceuticals Oyj

View Profile
Address
Joukahaisenkatu 6
Turku FP 20520
Finland
Employees -
Website http://www.faron.com
Updated 07/08/2019
Faron Pharmaceuticals Oy engages in the provision of biopharmaceutical development. The company focuses on novel treatments for medical conditions such as acute organ traumas, cancer immunotherapy and vascular damage. It operates through the Traumakine and Clevegen brands for acute respiratory distress syndrome, and for pre-clinical anti-Clever-1 antibody respectively.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.